Effect of sacha inchi oil (Plukenetia volúbilis L) on the lipid profile of patients with Hyperlipoproteinemia;Efecto del aceite de sacha inchi (Plukenetia volúbilis L) sobre el perfil lipídico en pacientes con Hiperlipoproteinemia

Revista Peruana de Medicina Experimental y Salud Publica

Volumn 28, Issue 4, 2011, Pages 628-632

  Garmendia, Fausto ^a,b   Pando, Rosa ^a,c   Ronceros, Gerardo ^a,c  

^a UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

^b Unidad de Investigación CARDIOGOLF   (Peru)

^c HOSPITAL NACIONAL DOS DE MAYO   (Peru)

Author keywords

Hypercholesterolemia; Hyperlipoproteinemias; Plukenetia volubilis L

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; PLANT MEDICINAL PRODUCT; SACHA INCHI OIL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPERIMENTAL STUDY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPOPROTEINEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MEDICINAL PLANT; OPEN STUDY; PILOT STUDY; PLUKENETIA VOLUBILIS; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84857079758     PISSN: 17264634     EISSN: 17264642     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sabaté J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Arch Intern Med. 2010; 170(9):821-7.
2. Tapsell LC, Gillen LJ, Patch CS, Batterham M, Owen A, Baré M, et al. Including walnuts in a low-fat/modifed-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care. 2004;27(12):2777-83.
3. Pascual G, Mejía M. Extracción y caracterización de aceite de sacha inchi (Plukenetia Volubilis L). Anales Científcos UNALM. 2000;42:143-57.
4. Guillén MD, Ruiz A, Cabo N, Chirinos R, Pascual G. Characterization of sacha inchi (Plukenetia volubilis L) oil by FTIR spectroscopy and 1H NMR. Comparison with linseed oil. J Am Oil Chemts Society. 2003;80(8):755-62.
5. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008;6(3):391-409.
6. Huamán J, Chávez K, Castañeda E, Carranza S, Chávez T, Beltrán Y, et al. Efecto de la Plukenetia volubilis Linneo (sacha inchi) en la trigliceridemia posprandial. An Fac med. 2008;69(4):263-6.
7. Herbert PN, Assmann G, Gotto AM, Fredrickson DS. Familial lipoprotein defciency: Abetalipoproteinemia, hypobetalipoproteinemia, and Tangier disease. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds). The Metabolic Basis of Inherited Disease. 5th ed. New York: McGraw-Hill; 1983. p. 594.
8. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetología. 1985;28(7):412-9.
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
10. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfbrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-45.
11. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-57.
12. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-55.
13. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406-15.
14. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992;70(7):733-7.
15. Gorriti A, Arroyo J, Quispe F, Cisneros B, Condorhuamán M, Almora Y, et al. Toxicidad oral a 60 días del aceite de sacha inchi (Plukenetia volubilis L) y linaza (Linum usitatissimum L.) y determinación de la dosis letal 50 en roedores. Rev Peru Med Exp Salud Publica. 2010;27(3):352-60.
16. Dall T, Bays H. Addressing lipid treatment targets beyond cholesterol: a role for prescription omega-3 fatty acid therapy. South Med J. 2009;102(4):390-6.
17. Garmendia F, Brown AS, Reiber I, Adams PC. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study). Curr Med Res Opin. 2000;16(3):208-19.
18. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1(7285):785-9.